Curetis plans Q1 U.S. launch for Unyvero pneumonia test

By staff writers

December 23, 2019 -- Curetis is planning a first-quarter launch in the U.S. of its Unyvero lower respiratory tract infection cartridge for bronchoalveolar lavage samples, after the product was granted 510(k) clearance by the U.S. Food and Drug Administration.

Photomicrograph of human lung tissue specimen shows histopathology in Pneumocystis pneumonia, caused by Pneumocystis jirovecii
Photomicrograph of human lung tissue specimen shows histopathology in Pneumocystis pneumonia, caused by Pneumocystis jirovecii. Image courtesy of the CDC/Lois Norman.

Designed for use with the company's Unyvero system, the LRT bronchoalveolar panel screens for pneumonia and other respiratory infections. It detects a broad range of causes of infections, including atypical pathogens, such as the fungus Pneumocystitis jirovecii, and screens for antibiotic resistance markers, which is helpful for guiding treatment decisions, according to the company.

This is the first panel cleared by the FDA that includes Pneumocystitis jirovecii, which is a leading cause of pneumonia in immunocompromised patients and is difficult to identify, Curetis noted. Culture-based diagnosis is not possible and the techniques used are labor-intensive, whereas the Unyvero is a rapid molecular test, the company said.

State of the IVD market: New cancer and infectious disease tests emerge
The North American IVD market is worth an estimated $31 billion in 2019 and is expected to reach $37 billion by 2024, reports Bruce Carlson,...
Hardy Diagnostics launches 15-minute resistance test
Hardy Diagnostics has launched a multiplex immunoassay for detecting the five most common carbapenemase enzymes produced by Enterobacteriaceae...
MicroRNAs predict problems in pneumonia patients
Certain small molecules involved in lung and systemic inflammatory processes show promise as affordable blood-based biomarkers for pneumonia patients...
ATS, IDSA revamp pneumonia testing guidance
More microscopic studies of respiratory tract samples are needed in some patients with pneumonia to reduce the risk of treating drug-resistant infections,...
C-reactive protein tests help curb antibiotic use in acute COPD
Point-of-care testing for the inflammatory marker C-reactive protein helped reduce the use of antibiotics for acute cases of chronic obstructive pulmonary...

Copyright © 2019

Last Updated np 12/23/2019 12:41:58 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current